Dose Escalation

Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3
John Powderly, Gregory Cote, Keith Flaherty, Russell Z Szmulewitz, Antoni Ribas, Jeffrey Weber, Deryk Loo, Jan Baughman, Francine Chen, Paul Moore, Ezio Bonvini, James Vasselli, Jon Wigginton, Roger Cohen, Howard Burris, Bartosz Chmielowski

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) O8; DOI: 10.1186/2051-1426-3-S2-O8
A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer
Jan Baughman, Deryk Loo, Francine Chen, Paul Moore, Ezio Bonvini, James Vasselli, Jon Wigginton, Roger Cohen

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P177; DOI: 10.1186/2051-1426-3-S2-P177

Main menu